1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Neuron BioPharma - Product Pipeline Review - 2013

Neuron BioPharma - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 30 pages

Neuron BioPharma - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Neuron BioPharma - Product Pipeline Review - 2013” provides data on the Neuron BioPharma’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Neuron BioPharma’s corporate website, SEC filings, investor presentations and featured press releases, both from Neuron BioPharma and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Neuron BioPharma - Brief Neuron BioPharma overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Neuron BioPharma human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Neuron BioPharma with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Neuron BioPharma’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Neuron BioPharma’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Neuron BioPharma in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Neuron BioPharma’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Neuron BioPharma.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Neuron BioPharma and identify potential opportunities in those areas.

Table Of Contents

Neuron BioPharma - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Neuron BioPharma Snapshot 5
Neuron BioPharma Overview 5
Key Information 5
Key Facts 5
Neuron BioPharma - Research and Development Overview 6
Key Therapeutic Areas 6
Neuron BioPharma - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Neuron BioPharma - Pipeline Products Glance 11
Neuron BioPharma - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Neuron BioPharma - Drug Profiles 12
FRP-0924 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
NPS-0155 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
NST-0003 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
NST-0004 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
NST-0005 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
NST-0021 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
NST-0037 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
NST-0060 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
NST-0076 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
NST-0078 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Neuron BioPharma - Pipeline Analysis 22
Neuron BioPharma - Pipeline Products by Therapeutic Class 22
Neuron BioPharma - Pipeline Products by Target 23
Neuron BioPharma - Pipeline Products by Molecule Type 24
Neuron BioPharma - Pipeline Products by Mechanism of Action 25
Neuron BioPharma - Recent Pipeline Updates 26
Neuron BioPharma - Dormant Projects 27
Neuron BioPharma - Locations And Subsidiaries 28
Head Office 28
Other Locations and Subsidiaries 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30



List of Tables

Neuron BioPharma, Key Information 5
Neuron BioPharma, Key Facts 5
Neuron BioPharma - Pipeline by Indication, 2013 8
Neuron BioPharma - Pipeline by Stage of Development, 2013 9
Neuron BioPharma - Monotherapy Products in Pipeline, 2013 10
Neuron BioPharma - Preclinical, 2013 11
Neuron BioPharma - Pipeline by Therapeutic Class, 2013 22
Neuron BioPharma - Pipeline by Target, 2013 23
Neuron BioPharma - Pipeline by Molecule Type, 2013 24
Neuron BioPharma - Pipeline Products by Mechanism of Action, 2013 25
Neuron BioPharma - Recent Pipeline Updates, 2013 26
Neuron BioPharma - Dormant Developmental Projects,2013 27
Neuron BioPharma, Subsidiaries 28



List of Figures

Neuron BioPharma - Pipeline by Top 10 Indication, 2013 7
Neuron BioPharma - Pipeline by Top 10 Therapeutic Class, 2013 22
Neuron BioPharma - Pipeline by Top 10 Target, 2013 23



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Galena Biopharma, Inc. (GALE) - Financial and Strategic SWOT Analysis Review

Galena Biopharma, Inc. (GALE) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Galena Biopharma, Inc. (Galena) is a biotechnology company that discovers, develops and commercializes therapies for the treatment of unmet medical needs, and advance care. Its pipeline products ...

ARCA biopharma, Inc. (ABIO) - Financial and Strategic SWOT Analysis Review

ARCA biopharma, Inc. (ABIO) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc., is a biopharmaceutical company. The company focuses on the development of genetically targeted therapies for cardiovascular diseases. Its product ...

Can-Fite BioPharma Ltd. (CFBI) - Financial and Strategic SWOT Analysis Review

Can-Fite BioPharma Ltd. (CFBI) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Can-Fite BioPharma Ltd. (Can-Fite) is a biopharmaceutical company that concentrates on the discovery and clinical development of drugs. The company's pipeline product portfolio comprise CF101, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.